Kiniksa (Uk) Patent-Cliff Exposure & CMS Drug Spending Portfolio

Kiniksa (Uk) (US): 1 reconciled FDA prescription therapies, $98.4M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$98.4M
2024 Medicare Part D Spend$53.2M
2024 Medicaid Spend$45.2M
California HCAI SB 17 Filings1 WAC filings (max 17.4% 2-yr change)